Dr. Tim Morley, Aquapharm’s Chief Scientific Officer, said: ‘We are very pleased with the output of our drug discovery platform based on marine microorganisms. From an initial screening of a little portion of our natural product library we’ve identified 16 novel substances belonging to totally novel and diverse chemical classes. The most advanced compound AQP-182 includes a promising pharmacokinetic and pharmacological profile which is pertinent for the treating hard to take care of extremely resistant bacterial infections’. Initial in vivo studies of AQP-182 recommend greater potency than the current ‘best-in-class’ drug utilized against MDRSA, and Aquapharm’s experts believe it could have the prospect of once-a-day dosing. A Phase I clinical trial is expected in the next half of 2013.A HEALTHCARE FACILITY ranked among both top 10 innovators in the healthcare industry, and one of many Top 20 Great Ideas, for defining and streamlining clinicians’ access to electronic health records, while keeping those information secure. The InformationWeek 500 yearly lists the leading IT innovators in the U.S. This year, the search positions placed The Children’s Hospital of Philadelphia as ninth within the health care industry and as amount 51 overall. In the entire list, CHOP was one of only three children’s hospitals in the very best 250 companies. We are really proud that our team’s efforts to really improve the usability and security of our electronic health records system were acknowledged by this respected national organization, said Bryan A.